Jeff Cehelsky - Concepedia

Author

Jeff Cehelsky

Alnylam Pharmaceuticals (United States)

Also Known As

J CEHELSKY, J. Cehelsky, Jeff Cehelsky

Publications

867

Citations

H-Index

Concepts

All Affiliations

Alnylam Pharmaceuticals (United States)University of Tennessee Health Science Center

About

Jeff Cehelsky is an author at Alnylam Pharmaceuticals (United States) specializing in medicine, pharmacotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	507
2	Immunology	3	3	87
3	Allergy	1	1	55
4	Biochemistry	1	1	13
5	Hepatology	1	1	54

Jeff Cehelsky

Publications

837

Citations

H-Index

Page 1

	Year	Citations
Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus John P. DeVincenzo, Tom Wilkinson, Akshay Vaishnaw, American Journal of Respiratory and Critical Care Medicine	2010	330
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV) John P. DeVincenzo, Jeff Cehelsky, Rene Alvarez, Antiviral Research Respiratory Syncytial VirusNeurovirologyPharmacologyAntiviral ResponseNovel Rnai	2008	245
Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group Katherine E. Warren, Regina I. Jakacki, Brigitte C. Widemann, Cancer Chemotherapy and Pharmacology Neuro-oncologyPediatric Brain TumorsPhase Ii TrialPediatric NeurosurgeryMedicine	2006	121
Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus Young‐In Kim, John P. DeVincenzo, Bart G. Jones, PLoS ONE VaccinationViral EvolutionMolecular VirologyAllergyNeurovirology	2014	55
Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. Andrés Cervantes, María Alsina, Josep Tabernero, Journal of Clinical Oncology Solid TumorsLiver InvolvementNovel Rnai TherapeuticPathologyPharmacotherapy	2011	54
Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients Amy Simon, Verena Karsten, Jeff Cehelsky, Lung TransplantationProgressive BronchiolitisRespiratory Syncytial VirusTransplantationPhase 2B	2012	19
Abstract 67: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Results for ALN-PCS, a Novel RNAi Therapeutic for the Treatment of Hypercholesterolemia Kevin Fitzgerald, Maria Frank-Kamenetsky, Timothy Mant, Arteriosclerosis Thrombosis and Vascular Biology Abstract 67Proprotein ConvertaseNovel Rnai TherapeuticGenetic EpidemiologyImmunology	2012	13

Page 1